AU2002211517A1 - Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits - Google Patents

Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits

Info

Publication number
AU2002211517A1
AU2002211517A1 AU2002211517A AU1151702A AU2002211517A1 AU 2002211517 A1 AU2002211517 A1 AU 2002211517A1 AU 2002211517 A AU2002211517 A AU 2002211517A AU 1151702 A AU1151702 A AU 1151702A AU 2002211517 A1 AU2002211517 A1 AU 2002211517A1
Authority
AU
Australia
Prior art keywords
detection
magnetic resonance
resonance imaging
imaging agents
amyloid deposits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211517A
Inventor
Matthew J. Allen
Scott Fraser
Russell E. Jacobs
Thomas J. Meade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology CalTech
Original Assignee
California Institute of Technology CalTech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology CalTech filed Critical California Institute of Technology CalTech
Publication of AU2002211517A1 publication Critical patent/AU2002211517A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AU2002211517A 2000-10-04 2001-10-04 Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits Abandoned AU2002211517A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23823100P 2000-10-04 2000-10-04
US60/238,231 2000-10-04
US28537901P 2001-04-20 2001-04-20
US60/285,379 2001-04-20
PCT/US2001/031415 WO2002028441A2 (en) 2000-10-04 2001-10-04 Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits

Publications (1)

Publication Number Publication Date
AU2002211517A1 true AU2002211517A1 (en) 2002-04-15

Family

ID=26931450

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211517A Abandoned AU2002211517A1 (en) 2000-10-04 2001-10-04 Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits

Country Status (3)

Country Link
US (1) US7029655B2 (en)
AU (1) AU2002211517A1 (en)
WO (1) WO2002028441A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
AU752812B2 (en) 1997-11-17 2002-10-03 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
WO2002016951A2 (en) 2000-08-21 2002-02-28 The General Hospital Corporation Methods for diagnosing a neurodegenerative condition
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
EP2298361A3 (en) * 2001-04-27 2011-05-04 The General Hospital Corporation Ocular diagnosis of Alzheimer's disease
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
AU2004206956A1 (en) * 2003-01-22 2004-08-05 The General Hospital Corporation Amyloid-binding, metal-chelating agents
JP3877754B2 (en) * 2003-10-30 2007-02-07 株式会社同仁化学研究所 Amyloid affinity compounds
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
CA2625196C (en) 2005-10-07 2016-04-05 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US20070258907A1 (en) * 2006-04-24 2007-11-08 Davis Mark E Polymer-coated paramagnetic particles
US8337813B2 (en) * 2007-09-14 2012-12-25 Northwestern University Contrast agents
KR100987592B1 (en) 2008-03-10 2010-10-12 경북대학교 산학협력단 MR Contrast Medium And Method For Preparing The Same
WO2009120995A2 (en) 2008-03-27 2009-10-01 Purdue Research Foundation Collagen-binding synthetic peptidoglycans, preparation, and methods of use
US8580231B2 (en) 2008-05-23 2013-11-12 Northwestern University Compositions and methods comprising magnetic resonance contrast agents
US20100029909A1 (en) * 2008-05-23 2010-02-04 Northwestern University Compositions and methods comprising magnetic resonance contrast agents
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
FR2942227B1 (en) 2009-02-13 2011-04-15 Guerbet Sa USE OF BUFFERS FOR RADIONUCLEID COMPLEXATION
WO2012003554A2 (en) * 2010-07-08 2012-01-12 Katholieke Universiteit Leuven Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates
WO2012078647A2 (en) * 2010-12-07 2012-06-14 Steven Verdooner Chemical composition to detect and treat amyloid in a patient's brain and retina
FR2968999B1 (en) 2010-12-20 2013-01-04 Guerbet Sa CHELATE NANOEMULSION FOR MRI
JP6212032B2 (en) * 2011-04-06 2017-10-18 ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム Lipid-based nanoparticles
JP6038122B2 (en) 2011-04-21 2016-12-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Functional magnetic nanoparticles and their use in image processing of amyloid deposits and neurofibrillary tangles
ES2708076T3 (en) 2011-05-24 2019-04-08 Symic Ip Llc Synthetic peptidoglycans that bind to hyaluronic acid, preparation and methods of use
FR2980364B1 (en) 2011-09-26 2018-08-31 Guerbet NANOEMULSIONS AND THEIR USE AS CONTRAST AGENTS
NL2007714C2 (en) 2011-11-04 2013-05-08 Academisch Ziekenhuis Leiden Lumc Imaging ligands.
CN104081416B (en) 2012-01-20 2018-10-02 A·安那普拉加达 Method and composition for objectively characterizing medical image
FR3001154B1 (en) 2013-01-23 2015-06-26 Guerbet Sa MAGNETO-EMULSION VECTORIZED
WO2014124334A2 (en) 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
JP6603650B2 (en) 2013-03-15 2019-11-06 パーデュー・リサーチ・ファウンデーション Extracellular matrix-bound synthetic peptidoglycan
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
CA2963941C (en) 2014-10-08 2023-08-01 Texas Children's Hosptial Mri imaging of amyloid plaque using liposomes
US9737698B2 (en) * 2016-01-04 2017-08-22 Givi Topchiashvili Method and system for treating patients with alzheimer disease
KR20200026263A (en) 2017-07-07 2020-03-10 시믹 아이피, 엘엘씨 Synthetic bioconjugates
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
CN112735799B (en) * 2020-12-10 2022-12-20 华东理工大学 Novel magnetic material and preparation method thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837169A (en) 1981-07-01 1989-06-06 Eastman Kodak Company Polypyridine Fluorescent labels for immunoassay
US4637988A (en) 1981-07-01 1987-01-20 Eastman Kodak Company Fluorescent labels for immunoassay
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US5188816A (en) 1984-10-18 1993-02-23 Board Of Regents, The University Of Texas System Using polyazamacrocyclic compounds for intracellular measurement of metal ions using MRS
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
ATE90879T1 (en) 1985-11-18 1993-07-15 Access Pharma Inc POLYCHELATING MATERIALS FOR IMAGE AND SPECTRAL ENHANCEMENT (AND SPECTRAL SHIFTING).
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US4877872A (en) 1986-06-24 1989-10-31 The University Of Toledo Production and use of dimers of hematoporophyrin, purpurins, chlorines and purpurin- and chlorin-complexes
US5219553A (en) 1986-08-04 1993-06-15 Salutar, Inc. Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
FR2604092B1 (en) 1986-09-19 1990-04-13 Immunotech Sa IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4867963A (en) * 1987-01-29 1989-09-19 Temple University Of The Commonwealth System Of Higher Education Enhancement of NMR imaging of tissue by paramagnetic pyrophosphate contrast agent
EP0299795B1 (en) 1987-07-16 1992-03-18 Nycomed As Aminopolycarboxylic acids and derivatives thereof
US5531978A (en) 1987-07-16 1996-07-02 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
US5162509A (en) 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5554748A (en) 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
US5230883A (en) 1989-05-04 1993-07-27 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors using polylysine complexes
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5446145A (en) 1990-01-19 1995-08-29 Nycomed Salutar, Inc. Polychelant compounds
WO1991010669A1 (en) 1990-01-19 1991-07-25 Cockbain, Julian, Roderick, Michaelson Chelating compounds
US5095099A (en) 1990-12-10 1992-03-10 E. I. Du Pont De Nemours And Company Fluorescent compounds for absorption and re-emission of radiation
US5310539A (en) 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
WO1992019264A1 (en) 1991-05-01 1992-11-12 University Of New Mexico Biomodulators as universal imaging agents
AU660033B2 (en) 1991-05-23 1995-06-08 Imarx Pharmaceutical Corp. Liposoluble compounds for magnetic resonance imaging
US5133956A (en) 1991-05-30 1992-07-28 The Dow Chemical Company Radiolabeled metal-binding protein for the treatment of arthritis
US5262532A (en) 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5407657A (en) 1992-09-22 1995-04-18 Unger; Evan C. Hybrid magnetic resonance contrast agents
US5466439A (en) 1992-11-12 1995-11-14 Magnetic Research, Inc. Polymeric contrast enhancing agents for magnetic resonance images
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US5358704A (en) 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
EP0661279B1 (en) 1993-12-30 2001-03-07 Guerbet Polyaminated ligands, metal complexes, process for their preparation and diagnostic and therapeutic applications
DE4403789A1 (en) 1994-02-03 1995-08-10 Schering Ag Means for visually marking body tissues
WO1995027705A1 (en) 1994-04-08 1995-10-19 Bracco International B.V. Aromatic amide compounds and metal chelates thereof
GB9407812D0 (en) 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
IT1269839B (en) 1994-05-26 1997-04-15 Bracco Spa CONJUGATES OF BILIARY ACIDS, THEIR DERIVATIVES WITH METALLIC COMPLEXES AND RELATED USES
US5622821A (en) 1994-06-29 1997-04-22 The Regents Of The University Of California Luminescent lanthanide chelates and methods of use
DE4428874A1 (en) 1994-08-08 1996-02-22 Schering Ag Dimer DTPA derivatives and their metal complexes, pharmaceutical compositions containing these complexes, their use in diagnostics and therapy, and methods for producing the complexes and compositions
TW319763B (en) 1995-02-01 1997-11-11 Epix Medical Inc
US5955605A (en) 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
EP1110945A3 (en) * 1995-05-01 2003-05-07 University Of Pittsburgh Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5980862A (en) 1995-06-02 1999-11-09 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US5707605A (en) 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
AU720841B2 (en) 1995-12-12 2000-06-15 California Institute Of Technology Cobalt schiff base compounds
IT1283218B1 (en) 1996-03-08 1998-04-16 Bracco Spa POLYKELANTS, THEIR COMPLEXES WITH METALLIC IONS, THEIR PREPARATION AND THEIR USES
ATE268187T1 (en) 1996-04-01 2004-06-15 Epix Medical Inc BIOACTIVATED DIAGNOSTIC IMAGING CONTRAST AGENTS
WO1997041856A1 (en) * 1996-05-08 1997-11-13 Massachusetts Institute Of Technology ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)
US5900228A (en) * 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
CA2307332C (en) 1997-10-27 2008-09-16 California Institute Of Technology Magnetic resonance imaging agents for the delivery of therapeutic agents
AU2001249795A1 (en) * 2000-04-04 2001-10-15 Mayo Foundation For Medical Education And Research Methods for detecting plaques in vivo

Also Published As

Publication number Publication date
WO2002028441A9 (en) 2003-02-20
WO2002028441A3 (en) 2002-06-13
US20020098153A1 (en) 2002-07-25
US7029655B2 (en) 2006-04-18
WO2002028441A2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
AU2002211517A1 (en) Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
EP1171032A4 (en) Methods for in vivo magnetic resonance imaging
AU2001251150A1 (en) Magnetic resonance imaging with resolution and contrast enhancement
AU1073601A (en) Fullerene contrast agent for magnetic resonance imaging and spectroscopy
AU2001229650A1 (en) Vessel delineation in magnetic resonance angiographic images
AU2002227276A1 (en) Accelerated magnetic resonance imaging
AU2002239655A1 (en) Contrast enhancement agent for magnetic resonance imaging
GB9926918D0 (en) Magnetic resonance imaging
IL149945A0 (en) Magnetic resonance imaging device
AU2002210847A1 (en) Magnetic resonance imaging device
EP1060706A4 (en) Magnetic resonance imaging device
AU2002235546A1 (en) 4 dimensional magnetic resonance imaging
EP1371327A4 (en) Magnetic resonance imaging apparatus and method
AU2002212600A1 (en) Magnetic resonance imaging device for operation in external static magnetic fields
AU2001280678A1 (en) Nuclear magnetic resonance measurements and methods of analyzing nuclear magnetic resonance data
EP1371328A4 (en) Magnetic resonance imaging apparatus and static magnetic field generating apparatus used therefor
IL146455A0 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
GB9926923D0 (en) Magnetic resonance imaging
GB9927358D0 (en) Endoscope suitable for magnetic resonance imaging
GB9912922D0 (en) Magnetic resonance imaging apparatus
AU3386799A (en) (in vivo) magnetic resonance vascular imaging using laser-polarized gas microbubbles
AU5085800A (en) Method of magnetic resonance imaging
IL146971A0 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
GB9923797D0 (en) Magnetic resonance imaging apparatus
EP1088513A4 (en) Magnetic resonance imaging device